ATMP | Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Advanced Therapy Medicinal Products

Regulatory Rapporteur September 2026 – Contents
2026-09-04T11:39:00+01:00
Navigating gene therapy development in Japan: The SYNAPSE Model for orchestrating interdependent PMDA consultations
2026-09-02T14:51:00+01:00
Managing ATMP lifecycle complexity: Navigating post-approval CMC divergence in Asia-Pacific
2026-09-02T10:58:00+01:00
Regulatory Rapporteur March 2026 – Contents
2026-03-06T09:18:00+00:00
Beyond product approval: Bridging the gap between regulatory success and patient access for biosimilars
2026-03-05T14:52:00+00:00
Navigating Advanced Therapy Medicinal Product regulatory changes: European Medicines Agency and UK guidance updates
2026-03-04T17:04:00+00:00

Cell therapy, gene therapy and tissue-engineered product manufacturing: Technical challenges, enablers and regulatory evolution
2026-03-04T15:08:00+00:00
HM9: From barrier to bridge – Practical strategies for successful advanced therapy medicinal product (ATMP) development
2025-11-18T09:57:00+00:00
HM4: Revision of the EU Variation Regulation – Continuing innovation in lifecycle management
2025-11-18T09:55:00+00:00
November 2025 – Contents: Medical devices/IVD sessions
2025-11-17T17:58:00+00:00
November 2025 – Contents: Human medicines sessions
2025-11-17T15:42:00+00:00
Regulatory Rapporteur November 2025 – Contents
2025-11-17T15:09:00+00:00

More ATMP content